Joy Wang

Advise executive leadership teams, boards, and investors on enterprise-level strategy and platform decisions at inflection points with material downside risk across life sciences and advanced modalities. Focus on high-stakes judgment under real-world constraints — including portfolio direction, scalability and feasibility limits, cross-regional structuring, and long-horizon value creation — where decisions must be made before full information is available. Selected focus areas: * Enterprise portfolio strategy & decision framing * Scalability and irreversibility assessment in advanced modalities * Capital discipline and risk-bounded growth * Cross-regional strategy and governance (U.S.–EU–Asia)

Commercial-stage autologous cell therapy company undergoing strategic transformation from a single-product organization into a pipeline-driven platform. Led enterprise-level strategy and strategic business development under highly irreversible scalability, cost, and execution constraints. Designed and selectively executed low-irreversibility pipeline expansion approaches (incubation, option-based partnerships, alliances) to manage capital risk and technological uncertainty. Structured non-dilutive and alliance-based mechanisms (e.g., CIRM IRP) to de-risk early pipeline development. Supported executive leadership and Board discussions by framing strategic trade-offs, sequencing, and pacing decisions.

Enterprise-level role leading global strategy, M&A, portfolio shaping, and cross-functional strategic initiatives across the Pharma business.

Supported portfolio transformation from generics-heavy assets toward more complex and innovative modalities. Used BD as a decision tool to stress-test pipeline assumptions and reshape portfolio direction. Integrated decision-critical input across research, development, and technical operations to inform governance and capital allocation.

Business Development & Licensing, deal transaction for U.S. market.

• Lead business development initiatives for Simcere Pharmaceutical Group and BioSciKin Venture Capital in the U.S. and Europe. • Identify and pursue partnership opportunities for in-licensing and equity investments. • Initiate business discussions and spearhead term sheet and contract negotiations.

Responsible for the neurodegenerative diseases, depression, bipolar depression, schizophrenia, and insomnia therapeutic areas within the Neuroscience New Product Planning (NPP) team; Led NPP Market Research, Payer Reimbursement Access, Global Strategic Pricing, Forecasting, Global Health Outcomes and participated in Core Team meetings to provide strategic guideline for early phase assets; outlined marketplace landscape (patient, payer, physician) and created Draft Launch Labels; interacted with the US, ACE, and Japan affiliates to ensure pipeline clarity; initiated shallow/deep dives from the Global perspective to capture market understanding.

Built and maintained strong professional relationships with physicians in public and military hospitals, office staffs and others in the patient care continuum. Organized territory program, group selling and conducted academic journal clubs. Fostered team effectiveness and accomplished market share growth and improved sales performance in the territory.

Developed business plan for chain Radiation Oncology Clinics in China. In charge of strategic marketing, medical/FDA regulations. Advised on insurance/reimburssement policy, created business model and operation strategy

Advised in regulatory, investment, business model and government policies

Developed business plan for financing and commercializing the project of Nano-tech based cancer detector developed by UCLA NanoSystems Institute (CNSI), Institute for Molecular Medicine (IMED); fund raising and led the negotiation with China pharmaceutical industrial investors in manufacture and commercial distribution

Patch-clamp electrophysiology and biomedical study of GABAA-receptor mediated inhibitory transmission in CNS. Learning and memory dysfunctions.